Systémová enzymoterapie pro odborníky

The use of WOBENZYM^® to facilitate interferon synthesis in the treatment of chronic urogenital chlamydiosis

Sukhikh G.T., Loginova N.S., Faizullin L.Z., Zdanov A.V, Malinina E.V, Bozedomov VA.

Scientific Center of Obstetrics, Gynecology and Perinatology of the Russian Academy of Medical Sciences and the International Institute of Biological Medicine, 117815, 4 Oparin Street, Moscow, Russia.

Int. J. Immunotherapy 1997, Vol XIII, No. 3/4, pp 131-133

SO 112 (19-04-2) - (5-02-2)

Summary

Chlamydial infections are recognized as a major cause of infertility in couples and different types of pathology of male and female reproductive functions. Female endocervical smears and male urethral swabs were examined by polymerase chain reaction (PCR) in 3,200 patients. Optimal schedule of treatment of chronic urogenital chlamydiosis using proteolytic enzymes (peroral tablet of Wobenzym^®, Mucos Pharma, Geretsried, Germany) were proposed by us. In order to realize the mechanism of the therapeutic effect of proteinases we investigated the changes in the interferon system of patients. We found significant decrease of IFN a-g production and increase of serum IFN. Application of Wobenzym^® led to normalization of leukocyte capability to synthesize IFN in response to all inductors. Standard antibiotic therapy led to chlamydia elimination in 61 % women and 45% men; combination of antibiotic therapy with Wobenzym^® resulted in 92% cases with women and 89.5% with men, respectively. The blockade of interferon synthesis by leukocytes seems to be the cause of long-term prolongation of chlamydial infection inducing inflammation in the genital tract. Proteinases coming into the blood relieve the blockade of non-specific antibacterial defense. Thus, proteolytic enzymes were shown as a highly efficient strengthening factor for antibiotic therapy of urogenital chlamydiosis.


Úvod pro odborníky O firmě Kontakty Pomáháme druhým Poradna
Zánět a jeho ovlivnění SET Zvýšení využitelnosti antibiotik proteolytickými enzymy Angiologie, flebologie Diabetologie Gynekologie Chirurgie, traumatologie, ortopedie Imunologie Lymfologie ORL Pediatrie Revmatologie Sportovní medicína Stomatologie Urologie Literatura Časopisy s Impact faktorem Ostatní literatura SPC Wobenzym SPC Phlogenzym	The use of WOBENZYM^® to facilitate interferon synthesis in the treatment of chronic urogenital chlamydiosis Sukhikh G.T., Loginova N.S., Faizullin L.Z., Zdanov A.V, Malinina E.V, Bozedomov VA. Scientific Center of Obstetrics, Gynecology and Perinatology of the Russian Academy of Medical Sciences and the International Institute of Biological Medicine, 117815, 4 Oparin Street, Moscow, Russia. Int. J. Immunotherapy 1997, Vol XIII, No. 3/4, pp 131-133 SO 112 (19-04-2) - (5-02-2) Summary Chlamydial infections are recognized as a major cause of infertility in couples and different types of pathology of male and female reproductive functions. Female endocervical smears and male urethral swabs were examined by polymerase chain reaction (PCR) in 3,200 patients. Optimal schedule of treatment of chronic urogenital chlamydiosis using proteolytic enzymes (peroral tablet of Wobenzym^®, Mucos Pharma, Geretsried, Germany) were proposed by us. In order to realize the mechanism of the therapeutic effect of proteinases we investigated the changes in the interferon system of patients. We found significant decrease of IFN a-g production and increase of serum IFN. Application of Wobenzym^® led to normalization of leukocyte capability to synthesize IFN in response to all inductors. Standard antibiotic therapy led to chlamydia elimination in 61 % women and 45% men; combination of antibiotic therapy with Wobenzym^® resulted in 92% cases with women and 89.5% with men, respectively. The blockade of interferon synthesis by leukocytes seems to be the cause of long-term prolongation of chlamydial infection inducing inflammation in the genital tract. Proteinases coming into the blood relieve the blockade of non-specific antibacterial defense. Thus, proteolytic enzymes were shown as a highly efficient strengthening factor for antibiotic therapy of urogenital chlamydiosis.
	Lék pro vnitřní užití. Čtěte pečlivě příbalovou informaci. Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750 003